Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management

Similar documents
Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management

Oncology, Colorectal Surgery, Gastroenterology, Internal Medicine, Family Practice, General Surgery, Geriatric Medicine, Multispecialty

NCQA that the exclusion still applies.

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Date Modified: May 29, Clinical Quality Measures for PQRS

Date Modified: March 31, Clinical Quality Measures for PQRS

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures

Prostate Cancer Dashboard

Radiotherapy Of Prostate Cancer

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment

Chapter 18: Glossary

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Coding Companion for Oncology/Hematology. A comprehensive illustrated guide to coding and reimbursement

COLORECTAL CANCER SCREENING

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS

Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

Patient Identification Quiz

MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER

Measure Description. Denominator Statement

Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

Cancer Endorsement Maintenance 2011-Maintenance Measures

Measure Specifications Measure Description

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

Physician Self-Referral: Recent Research from the Government Accountability Office (GAO)

BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

How ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA

NATIONAL QUALITY FORUM

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

TOOKAD (padeliporfin) Patient Information Guide

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013

The European Board of Urology

LDR prostate brachytherapy

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

NCD for Medicine: Human Chorionic Gonadotropin(190.27)

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Percentage of patients who underwent endoscopic procedures following SWL

Open clinical uro-oncology trials in Canada

Prostate Cancer in men with germline DNA repair deficiency

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation

One Stop Prostate Biopsy Protocol Author Consultation Date Approved

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS

Troubleshooting Audio

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT

Prostate cancer. Treatments Side effects and management in the community setting

Non-QPP Measures. # Measure Title Definition Type Domain. Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

creatinine lab order placed abdomen, MRI abdomen, ultrasound abdomen ordered or performed

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer.

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Newer Aspects of Prostate Cancer Underwriting

Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320

Corporate Medical Policy

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Prostate Cancer Update 2017

Corporate Medical Policy

THE UROLOGY GROUP

Cryosurgical Ablation of Breast Fibroadenomas

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

Faster Cancer Treatment Indicators: Use cases

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date

2014 Oncology Measures Group Overview

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018

Tobacco Use: Screening & Cessation Intervention

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Open clinical uro-oncology trials in Canada

MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

Measure Information Form

The Selenium and Vitamin E Prevention Trial

Prostate Overview Quiz

AllinaHealthSystems 1

Transcription:

Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (625) Measure Code: PRS Rule : Applicable Provider Specialty: General Criteria Summary Steward: Active Health Management Lab Data: Y Percentage of males with prostate cancer that have had their PSA monitored in the past 12 months Urology, Oncology, Internal Medicine, Family Practice, Geriatric Medicine, 1. Measurement period: 1 year prior to measurement period end date 2. Continuous enrollment: 3. Anchor date: measurement period end date (ie. December 31 of calendar year) 4. Gaps in enrollment: One 45-day gap allowed in the measurement year 5. Medical coverage: Yes 6. Drug coverage: No 7. Attribution time frame: 1 year on all prostate cancer denominator events 8. Exclusions apply: Yes 9. Age range: 18 years or older as of the beginning of the measurement year Summary of changes for 2014 No changes ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Denominator : All male patients, 18 years or older as of the beginning of the measurement year with a diagnosis of prostate cancer any time prior to or during the measurement year Inclusion Criteria: All male patients, 18 years or older as of the beginning of the measurement year with a diagnosis of prostate cancer any time prior to or during the measurement year Eligibility Criteria Age is 18 years or older Age in Years >= 18 As of the beginning of measurement year Page 1

Claim Criteria Diagnosis of prostate cancer 1 Any Diagnosis Code = Prostate Cancer Value Set Any time prior to or during the measurement year Exclusion Criteria: Patients with prostate cancer treatment at any time during the measurement year OR Patients with diagnosis of metastatic disease during the measurement year OR Patients who have been in a skilled nursing facility during the measurement year Prostate Cancer treatment 1 (CPT Procedure Code = Prostate Cancer Treatment Value Set ICD 9 Procedure Codes = Prostate Cancer Treatment Value Set) OR Diagnosis of metastasis OR Patients in Skilled Nursing Facility 1 Any Diagnosis Code = Metastasis Value Set 1 (CPT Procedure Code = Skilled Nursing Facility Value Set UB Rev Code = Skilled Nursing Facility Value Set 1 Place of service code = Skilled Nursing Facility Value Set) Page 2

Continuous Enrollment Criteria: Continuous enrollment AND Has medical coverage Continuous Enrollment is 12 out of 12 months Coverage Indicator Medical = Y ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Numerator : Males in the denominator who had PSA monitoring anytime during the measurement year. Inclusion Criteria: Males in the denominator who had PSA monitoring anytime during the measurement year. PSA monitoring 1 CPT Procedure Code = PSA Monitoring Value Set HCPCS code = ICD-9 Diagnosis = LOINC codes = Page 3

Notes: Appendix Prostate Cancer Value Set Code Code Type 185 ICD-9-CM Diagnosis Malignant neoplasm of prostate Prostate Cancer Value Set Code Code Type 55801 CPT Prostatectomy, perineal, subtotal 55810 CPT Extensive Prostate Surgery 55812 CPT Extensive Prostate Surgery 55815 CPT Extensive Prostate Surgery 55821 CPT Removal of Prostate 55831 CPT Removal of Prostate 55840 CPT Extensive Prostate Surgery 55842 CPT Extensive Prostate Surgery 55845 CPT Extensive Prostate Surgery 55859 CPT Percut/Needle Insert - Pros 55860 CPT Surgical Exposure - Prostate 55862 CPT Extensive Prostate Surgery 55865 CPT Extensive Prostate Surgery 55866 CPT Laparo Radical Prostatectomy 77750 CPT Infuse Radioactive Materials 77761 CPT Apply Intrcav Radiat Simple Page 4

77762 CPT Apply Intrcav Radiat Interm 77776 CPT Apply Interstit Radiat Simpl 77777 CPT Apply Interstit Radiat Inter 77778 CPT Apply Interstit Radiat Compl 77781 CPT High Intensity Brachytherapy 77782 CPT High Intensity Brachytherapy 77783 CPT High Intensity Brachytherapy 77784 CPT High Intensity Brachytherapy 77799 CPT Radium/Radioisotope Therapy G0256 CPT Prostate brachytherapy implanting Palladium seeds G0261 CPT Prostate brachytherapy implanting iodine seeds 4164F CPT Adjuvant hormonal therapy 4200F CPT Prostate external beam radiotherapy as primary therapy 4201F CPT Prostate external beam radiotherapy to non-prostate only 60.3 ICD-9-PCS Procedure Suprapubic prostatectomy 60.4 ICD-9-PCS Procedure Retropubic prostatectomy 60.5 ICD-9-PCS Procedure Radical prostatectomy 60.6 ICD-9-PCS Procedure Other prostatectomy 60.61 ICD-9-PCS Procedure Local excision of lesion of prostate 60.62 ICD-9-PCS Procedure Perineal prostatectomy 60.69 ICD-9-PCS Procedure Other prostatectomy Metastasis Value Set Code Code Type 1970* ICD-9-CM Diagnosis Secondary Malig Neo Lung 1971* ICD-9-CM Diagnosis Sec Mal Neo Mediastinum 1972* ICD-9-CM Diagnosis Second Malig Neo Pleura 1973* ICD-9-CM Diagnosis Sec Malig Neo Resp NEC 1974* ICD-9-CM Diagnosis Sec Malig Neo Sm Bowel 1975* ICD-9-CM Diagnosis Sec Malig Neo Lg Bowel Page 5

1976* ICD-9-CM Diagnosis Sec Mal Neo Peritoneum 1977* ICD-9-CM Diagnosis Second Malig Neo Liver 1978* ICD-9-CM Diagnosis Sec Mal Neo GI NEC 1980* ICD-9-CM Diagnosis Second Malig Neo Kidney 1981* ICD-9-CM Diagnosis Sec Malig Neo Urin NEC 1982* ICD-9-CM Diagnosis Secondary Malig Neo Skin 1983* ICD-9-CM Diagnosis Sec Mal Neo Brain/Spine 1984* ICD-9-CM Diagnosis Sec Malig Neo Nerve NEC 1985* ICD-9-CM Diagnosis Secondary Malig Neo Bone 1986* ICD-9-CM Diagnosis Second Malig Neo Ovary 1987* ICD-9-CM Diagnosis Second Malig Neo Adrenal 1988* ICD-9-CM Diagnosis Second Malig Other Specified Sites Skilled Nursing Facility Value Set Code Code Type 99304-99306 CPT Nursing Facility Care - Init 99307-99310 CPT Nursing Fac Care - Subseq 99315-99316 CPT Nursing Fac Discharge Day 99318 CPT Annual Nursing Fac Assessmnt 055* UB Revenue Skilled Nursing 31 Place of Service Skilled Nursing Facility Code Code Type 84152 CPT Assay of Psa - Complexed 84153 CPT Assay of Psa - Total 84154 CPT Assay of Psa - Free G0103 HCPCS Psa - Total Screening 790.93 ICD-9-CM Diagnosis Elvtd Prstate Spcf Antgn Page 6

2857-1 LOINC Prostate specific Ag 10886-0 LOINC Prostate specific Ag.free 12841-3 LOINC Prostate specific Ag.free/Prostate specific Ag.total 19195-7, 19197-3 LOINC Prostate specific Ag 19201-3, 19203-9 LOINC Prostate specific Ag.free 33667-7 LOINC Prostate specific Ag.protein bound 35741-8 LOINC Prostate specific Ag Page 7